These lead to the exploration of anti-EGFR agents in HCC therapy and four anti-EGFR strategies have been probed: small molecule TKIs (Erlotinib), Erlotinib plus Bevacizumab, Erlotinib plus Sorafenib and Cetuximab [35,36,37,38,39,40]. This evidence concerns the gene EGFR and hepatocellular carcinoma.